Autoimmune disease company Oblenio Bio clinches $62M led by Pfizer Ventures

Oblenio Bio raises $62M Series B led by Pfizer Venture Investments to advance LBL-051, a trispecific TCE targeting BCMA, CD19, and CD3, into first-in-human trials for autoimmune disease.

Raccontata daendpoints.news